Figure 6

CEACAM6 expression in tumours treated with a PI3K/AKT inhibitor. A) Subconfluent cultures of Detroit 562 cells transduced with vector (pLV101), knockdown construct (mir CEA Dux) or overexpression vector (pLV101-CEA) were exposed to varying concentrations of BGT226 for 48 hours after which viability was assessed. Data presented as mean ± sem from 2 experiments performed in triplicate. B) Protein was harvested from untreated cells used in (A) and CEACAM6, AKT or phospho-S437 AKT protein expression estimated by western blot. β-actin expression is presented to confirm loading equivalence. C) 10⁶ cells used in (A) were injected into NOD/SCID mice and when tumours reached 0.4 cm³ the mice were treated with daily doses of vehicle or BGT226 as described elsewhere[13]. Mice were sacrificed when tumours reached 1 cm³ and tumours removed, fixed and 5 μm sections stained for CEACAM6 expression. Note mice treated with BGT226 displayed significant reductions in tumour growth and time to sacrifice was significantly extended in these mice[13]. An IgG negative control is shown on the left. Six mice per group were used and a representative section from one mouse is shown. 20X magnification.